In a dazzling display of financial finesse, Assenagon Asset Management S.A. has significantly increased its shareholding in Alnylam Pharmaceuticals, Inc. by a staggering 2,649.3% during the first quarter of this year. According to the company’s recent filing with the esteemed Securities and Exchange Commission (SEC), Assenagon Asset Management S.A. now possesses an impressive 215,191 shares of the renowned biopharmaceutical company’s stock. The acquisition of an additional 207,364 shares during this period has propelled Assenagon Asset Management S.A.’s stake in Alnylam Pharmaceuticals to new heights.
The value of such a substantial investment is indeed awe-inspiring, as these shares are currently estimated to be worth a remarkable $43,107,000 at the close of the most recent quarter. This noteworthy increase in ownership stakes firmly establishes Assenagon Asset Management S.A. as a major player within Alnylam Pharmaceuticals, commanding an impressive 0.17% ownership interest.
Alnylam Pharmaceuticals stands at the forefront of biopharmaceutical innovation and excellence. They have dedicated themselves to discovering, developing, and commercializing novel therapeutics derived from ribonucleic acid interference technology – or RNAi for short. The company’s pipeline consists of cutting-edge investigational RNAi therapeutics that focus on various areas such as genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
Market analysts have scrutinized Alnylam Pharmaceuticals’ performance closely in recent times and have provided pertinent insights regarding its potential future trajectory. JPMorgan Chase & Co., for instance, reduced their target price for Alnylam Pharmaceuticals from $200 to $196 while maintaining a “neutral” rating on the company in their comprehensive research notes released on Friday, March 3rd.
Furthermore, Sanford C. Bernstein commenced their coverage on Alnylam Pharmaceuticals on Tuesday, March 21st, offering a promising “outperform” rating and setting a target price of $243. HC Wainwright reiterated a resolute “buy” rating and set an ambitious target price of $415 for shares of Alnylam Pharmaceuticals on Friday, March 3rd. These ratings and predictions showcase the significant potential for growth that Alnylam Pharmaceuticals possesses.
Morgan Stanley also joined the chorus, raising their price target from $205 to $210 and granting the stock an “equal weight” rating in their research note published on Tuesday, April 4th. Lastly, BMO Capital Markets lauded Alnylam Pharmaceuticals with an upgraded rating from “market perform” to “outperform,” along with an increase in their price target from $200 to $250 in their research note released on Friday, May 5th.
In light of these financial assessments, it is notable that six research analysts have deemed the stock worthy of a hold rating while fourteen have passionately endorsed it as a buy. This vibrant embrace by industry experts highlights both confidence in Alnylam Pharmaceuticals’ future prospects and recognition of its significant achievements thus far.
When looking at Bloomberg’s comprehensive data analysis, it becomes apparent that Alnylam Pharmaceuticals boasts a consensus rating of “Moderate Buy” accompanied by an average price target of $247.20 – further reinforcing the positive sentiment surrounding this biopharmaceutical powerhouse.
As Assenagon Asset Management S.A. asserts its expanding dominance in the pharmaceutical realm through its audacious investment strategy, Alnylam Pharmaceuticals continues to drive innovation within the biopharmaceutical sector. With its groundbreaking RNAi technology paving the way for revolutionary therapeutics, Alnylam Pharma is poised for further success on its mission to transform healthcare as we know it.
[bs_slider_forecast ticker=”ALNY”]
Institutional Investors Show Interest in Alnylam Pharmaceuticals, While Insider Selling Raises Questions
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”ALNY” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]Alnylam Pharmaceuticals, Inc. has recently gained attention from institutional investors and hedge funds, with several of them making significant modifications to their holdings of the company. Belpointe Asset Management LLC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter, valued at approximately $25,000. Similarly, ANTIPODES PARTNERS Ltd acquired a new stake in the company during the same period, with an investment value of around $28,000. Northwestern Mutual Wealth Management Co. increased its stake by 59.4% in the fourth quarter and now owns 373 shares valued at $89,000 after purchasing an additional 139 shares.
CI Investments Inc. also saw a substantial increase in its holdings, with a 52.7% stake expansion during the third quarter. The firm now possesses 394 shares worth $79,000 after acquiring an additional 136 shares in the last quarter. Harvest Fund Management Co. Ltd showed interest as well by purchasing a new stake valued at approximately $95,000 during the fourth quarter.
It is worth mentioning that institutional investors currently own an impressive 94.43% of Alnylam Pharmaceuticals’ stock.
In other news related to the company’s financial affairs, EVP Indrani Lall Franchini recently sold off 3,500 shares of Alnylam Pharmaceuticals’ stock on April 6th for a total value of $735,000 or an average price of $210 per share. Another transaction involving EVP Indrani Lall Franchini took place on that same day when she sold another 3,500 shares for identical monetary worth and price range.
Furthermore, CEO Yvonne Greenstreet also made a significant sale on April 27th by selling 7,615 shares of the biopharmaceutical company’s stock for an average price of $194.59 each, amounting to a total value of $1,481,802.85. Following this transaction, the CEO now holds direct ownership of 30,332 shares valued at approximately $5,902,303.88.
It is interesting to note that over the past 90 days, insiders have sold a total of 17,799 shares valued at $3,517,442. This corresponds to a mere 1.40% of the stock’s ownership by the company insiders.
Alnylam Pharmaceuticals focuses on discovering, developing, and commercializing innovative therapeutics based on ribonucleic acid interference (RNAi). This cutting-edge technology holds immense potential in genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. The company has an extensive pipeline of investigational RNAi therapeutics that aim to revolutionize the medical field.
On Thursday, ALNY stock opened at $196.56. The company demonstrates stability with its fifty-day moving average price at $197.07 and its two-hundred-day moving average price at $208.26. Over the period of one year, Alnylam Pharmaceuticals has shown a one-year low of $135.46 and a high of $242.97 per share. With a market cap amounting to roughly $24.48 billion and a beta score of 0.48; however intriguing investors may find it; they must remain cautious about its negative price-to-earnings ratio standing at -22.62.
During its latest quarterly earnings release on May 4th, Alnylam Pharmaceuticals reported earnings per share (EPS) of ($1.40), surpassing analysts’ consensus estimates by approximately $0.57 which was initially predicted as ($1.97). The company also revealed that it had experienced negative net margins amounting to 93.13% and negative return on equity reaching an astounding figure of -1,287.80%. However, despite these otherwise alarming figures, Alnylam Pharmaceuticals managed to achieve revenue of $319.29 million during the quarter, surpassing analysts’ expectations of $312.53 million. Additionally, the company experienced a 49.7% increase in revenue compared to the same quarter in the previous year.
Research analysts anticipate that Alnylam Pharmaceuticals, Inc.’s EPS for the current fiscal year will be an estimated -6.52.
In conclusion, while Alnylam Pharmaceuticals garners significant attention from institutional investors and hedge funds with increased stakes and acquisitions, it is crucial to consider the recent insider-selling activities carried out by EVP Indrani Lall Franchini and CEO Yvonne Greenstreet. Despite a negative price-to-earnings ratio and considerable fluctuations in its stock price over the past year, Alnylam Pharmaceuticals has demonstrated impressive growth with substantial revenue increases in recent quarters. As researchers predict a less stellar performance in terms of earnings per share this fiscal year, investors are advised to exercise caution when deciding whether or not to invest in this biopharmaceutical company focused on RNA interference therapeutics.
